Equities analysts forecast that Acorda Therapeutics (NASDAQ:ACOR) will post $0.73 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Acorda Therapeutics’ earnings. The lowest EPS estimate is $0.50 and the highest is $1.02. Acorda Therapeutics reported earnings of ($0.08) per share in the same quarter last year, which suggests a positive year over year growth rate of 1,012.5%. The company is expected to issue its next quarterly earnings results before the market opens on Wednesday, May 2nd.
On average, analysts expect that Acorda Therapeutics will report full-year earnings of $0.03 per share for the current year, with EPS estimates ranging from ($0.15) to $0.33. For the next fiscal year, analysts expect that the business will report earnings of ($2.13) per share, with EPS estimates ranging from ($4.35) to $0.81. Zacks’ EPS calculations are a mean average based on a survey of research firms that follow Acorda Therapeutics.
Acorda Therapeutics (NASDAQ:ACOR) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $0.61 EPS for the quarter, missing the consensus estimate of $0.88 by ($0.27). Acorda Therapeutics had a negative return on equity of 4.88% and a negative net margin of 37.97%. The firm had revenue of $188.40 million for the quarter, compared to analyst estimates of $171.70 million. During the same quarter last year, the firm earned $0.05 EPS. The company’s revenue was up 34.0% on a year-over-year basis.
Several analysts recently commented on ACOR shares. HC Wainwright reiterated a “buy” rating and issued a $31.00 price target (down previously from $34.00) on shares of Acorda Therapeutics in a research report on Wednesday, January 17th. BidaskClub cut shares of Acorda Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 28th. Oppenheimer reaffirmed a “hold” rating on shares of Acorda Therapeutics in a research note on Wednesday, March 21st. Zacks Investment Research cut shares of Acorda Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Finally, JPMorgan Chase reaffirmed a “hold” rating on shares of Acorda Therapeutics in a research note on Tuesday, January 9th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and three have assigned a buy rating to the company. Acorda Therapeutics has a consensus rating of “Hold” and a consensus price target of $21.83.
Shares of NASDAQ:ACOR opened at $23.35 on Wednesday. Acorda Therapeutics has a twelve month low of $13.60 and a twelve month high of $29.60. The company has a market cap of $1,097.78, a PE ratio of 22.45 and a beta of 1.59. The company has a quick ratio of 2.81, a current ratio of 3.07 and a debt-to-equity ratio of 0.64.
Several hedge funds have recently made changes to their positions in ACOR. Meadow Creek Investment Management LLC lifted its holdings in shares of Acorda Therapeutics by 56.0% during the 4th quarter. Meadow Creek Investment Management LLC now owns 8,736 shares of the biopharmaceutical company’s stock worth $187,000 after acquiring an additional 3,136 shares during the period. Teacher Retirement System of Texas purchased a new position in shares of Acorda Therapeutics during the 4th quarter worth about $347,000. MetLife Investment Advisors LLC purchased a new position in shares of Acorda Therapeutics during the 4th quarter worth about $439,000. UBS Asset Management Americas Inc. lifted its holdings in shares of Acorda Therapeutics by 10.0% during the 4th quarter. UBS Asset Management Americas Inc. now owns 23,177 shares of the biopharmaceutical company’s stock worth $497,000 after acquiring an additional 2,100 shares during the period. Finally, Acadian Asset Management LLC purchased a new position in shares of Acorda Therapeutics during the 4th quarter worth about $537,000.
COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect Acorda Therapeutics (ACOR) to Post $0.73 Earnings Per Share” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://ledgergazette.com/2018/04/21/zacks-analysts-expect-acorda-therapeutics-acor-to-post-0-73-earnings-per-share.html.
About Acorda Therapeutics
Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.